Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Therapeutic studies.

L V Rubinstein1

  • 1Biometric Research Branch, National Cancer Institute, Bethesda, Maryland, USA. rubinsteinl@ctep.nci.nih.gov

Hematology/Oncology Clinics of North America
|August 19, 2000
PubMed
Summary
This summary is machine-generated.

This article addresses challenges in cancer clinical trial design and interpretation across all phases. It details statistical solutions to ensure accurate results while prioritizing patient safety from ineffective or toxic treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial.

NPJ precision oncology·2022
Same author

Corrigendum to 'Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q': [Annals of Oncology 30 (2019) 1821-1830].

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q.

Annals of oncology : official journal of the European Society for Medical Oncology·2019
Same author

Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials.

British journal of cancer·2001
Same author

An information-intensive approach to the molecular pharmacology of cancer.

Science (New York, N.Y.)·1997
Same author

Enhanced sensitivity to 1-beta-D-arabinofuranosylcytosine and topoisomerase II inhibitors in tumor cell lines harboring activated ras oncogenes.

Cancer research·1996

Area of Science:

  • Oncology
  • Biostatistics
  • Clinical Trial Design

Background:

  • Cancer clinical trials (Phase I, II, III) face inherent design, conduct, and interpretation issues.
  • Ensuring accurate and precise answers to research questions is critical for advancing cancer treatment.
  • Protecting patients from excessive toxicity and lack of clinical efficacy is a primary ethical and scientific concern.

Purpose of the Study:

  • To identify and discuss fundamental problems in the design, conduct, and interpretation of cancer clinical trials.
  • To present statistical solutions addressing these challenges across all trial phases.
  • To highlight the common underlying problem and its influence on statistical designs.

Main Methods:

  • Review and analysis of common issues in Phase I, II, and III cancer clinical trials.

Related Experiment Videos

  • Explanation of statistical methodologies applied to overcome design and interpretation challenges.
  • Discussion of the fundamental problem of balancing scientific inquiry with patient safety.

    • Main Results:

    • Identified key problems in cancer clinical trial design, conduct, and interpretation.
    • Detailed various statistical approaches to resolve these issues.
    • Emphasized the shared challenge of achieving precise answers while ensuring patient safety.

    Conclusions:

    • Statistical solutions are crucial for addressing design and interpretation problems in cancer clinical trials.
    • A common fundamental problem across trial phases necessitates similar statistical design principles.
    • Effective statistical strategies are vital for informing future cancer treatment and testing.